Abstract 5502: Oral Anticoagulation Monotherapy versus Combination Antithrombotic Therapy with Antiplatelet Following TAVR in Patients on Chronic Oral Anticoagulation
Abstract
Introduction: Optimal antithrombotic management following transcatheter aortic valve replacement (TAVR) in patients with pre-existing indications for chronic oral anticoagulation (OAC) remains poorly defined. Current evidence, including the POPular TAVI trial, suggests OAC monotherapy may be sufficient, yet combination therapy with antiplatelet remains common in clinical practice. We evaluated clinical outcomes of OAC monotherapy versus OAC combined with antiplatelet therapy in this high-risk population using a large real-world dataset. Methods: We conducted a retrospective cohort study using the TriNetX Research Network (2020-2024) including adults on chronic OAC who underwent TAVR. Patients with prior valve replacement, rheumatic aortic stenosis, allergy to aspirin/clopidogrel, or coronary intervention within 3 months prior to TAVR were excluded. Patients were stratified into three cohorts based on antiplatelet use in the 3 months post-TAVR: OAC monotherapy, OAC + aspirin, and OAC + clopidogrel. Propensity score matching (1:1) was performed to balance baseline characteristics. Outcomes were assessed from TAVR through 1 year of follow-up. Hazard ratios (HR) were estimated using Cox proportional hazards regression. Statistical significance was defined as two-sided p<0.05. Results: A total of 12,900 patients on chronic OAC underwent TAVR, of whom 4,088 received OAC monotherapy, 7,137 received OAC + aspirin, and 1,675 received OAC + clopidogrel. Post-propensity score matching, baseline characteristics were well-balanced with mean ages of 81.4±8.1, 81.2±8.9, and 82.1±7.6 years, respectively, over a mean follow-up of 322±101 days. Compared with OAC monotherapy, OAC + aspirin was associated with significantly higher rates of major bleeding (intracranial hemorrhage and bleeding requiring transfusion) (HR 1.36; 95% CI 1.14-1.63; p<0.001), gastrointestinal bleeding (HR 1.49; 95% CI 1.20-1.86; p<0.001), non-GI bleeding (HR 1.37; 95% CI 1.16-1.63; p<0.001), major adverse cardiovascular events (HR 1.24; 95% CI 1.15-1.34; p<0.001), acute heart failure exacerbation (HR 1.21; 95% CI 1.11-1.32; p<0.001). OAC + clopidogrel was similarly associated with higher major bleeding (HR 1.34; 95% CI 1.02-1.77; p=0.04), GI bleeding (HR 1.64; 95% CI 1.13-2.39; p=0.009), and acute HF exacerbation (HR 1.17; 95% CI 1.02-1.34; p=0.03). No significant difference was observed across groups for all-cause mortality (OAC + aspirin: HR 1.08; p=0.29; OAC + clopidogrel: HR 0.93; p=0.50), valvular reintervention (HR 0.72; p=0.25), or valvular thrombosis (HR 0.98; p=0.94). Conclusions: In patients on chronic OAC undergoing TAVR, addition of antiplatelet therapy was associated with significantly higher rates of bleeding, major adverse cardiovascular events, and acute HF exacerbation, without reduction in all-cause mortality, valvular thrombosis and reintervention.